Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | Selecting and risk stratifying patients with DLBCL for ASCT

Sergio Giralt • 30 Sep 2022
SOHO 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T

In this video, Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, shares some insights into the role of autologous stem cell transplantation (ASCT) in patients with diffuse large B-cell lymphoma (DLBCL) and further comments on how patients are risk stratified for ASCT. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sergio Giralt

0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:12
An update in cellular therapies: gene editing for SCD and immunotherapies for MM
Sergio Giralt • 8 Dec 2023
0:59
The role of radioimmunoconjugates in AML treatment: insights from the SIERRA trial
Sergio Giralt • 8 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals